Discrepant MR and [F]Fluoroethyl-l-Tyrosine PET imaging findings in a patient with bevacizumab failure

Case Reports in Oncology

Volumn 5, Issue 3, 2012, Pages 490-494

  Galldiks, Norbert ^a,c   Filss, Christian P ^a,b   Goldbrunner, Roland ^c   Langen, Karl Josef ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b Juelich Aachen Research Alliance (JARA)   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

18F Fluoroethyl l tyrosine; Amino acid PET; Metabolically active tumor volume; RANO criteria; Volume of interest analysis

Indexed keywords

BEVACIZUMAB; FLUOROETHYL TYROSINE F 18; IRINOTECAN; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGITATION; ANTIANGIOGENIC THERAPY; APHASIA; ARTICLE; BRAIN BIOPSY; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CONTRAST ENHANCEMENT; DRUG DOSE INTENSIFICATION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG UPTAKE; DRUG WITHDRAWAL; FOLLOW UP; GLIOBLASTOMA; HEMIPARESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STEREOTACTIC BIOPSY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84873157004     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000342480     Document Type: Article

References (9)

1. Chamberlain MC: Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010;116:3988-3999.
2. Wick W, Wick A, Weiler M, Weller M: Patterns of progression in malignant glioma following anti-VEGF therapy: Perceptions and evidence. Curr Neurol Neurosci Rep 2011;11:305-312.
3. Ahluwalia MS, Wen PY: Antiangiogenic therapy for patients with glioblastoma: Current challenges in imaging and future directions. Expert Rev Anticancer Ther 2011;11:653-656.
4. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729.
5. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM: Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
6. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ: O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678-687.
7. Galldiks N, Kracht LW, Dunkl V, Ullrich RT, Vollmar S, Jacobs AH, Fink GR, Schroeter M: Imaging of non- or very subtle contrast-enhancing malignant gliomas with [(11)C]-methionine positron emission tomography. Mol Imaging 2011;10:453-459.
8. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M: One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-2115.
9. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, Muigg A, Virgolini IJ, Staffen W, Trinka E, Gotwald T, Jacobs AH, Stockhammer G: O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 2011;52:856-864.